Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 22Squamous Cell Carcinoma of Head and Neck 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 6Rectal Neoplasms 5Neoplasm Metastasis 5Mouth Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Colonic Neoplasms 5Pancreatic Neoplasms 4Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma 3Thyroid Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Endometrial Neoplasms 2Urologic Neoplasms 1Solid Tumors 1Soft Tissue Neoplasms 1Skin Neoplasms 1Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neurofibromatosis 1 1

Interventions

Cisplatin 5Gemcitabine 4Oxaliplatin 2Irinotecan 2Fluorouracil 2Capecitabine 2Bevacizumab 2zanidatamab 1toripalimab 1pembrolizumab 1niraparib 1neratinib 1ivosidenib 1futibatinib 1fludarabine 1envafolimab 1encorafenib 1durvalumab 1binimetinib 1Trastuzumab 1Pemetrexed 1Nivolumab 1Folfox protocol 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Actigraphy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Cetuximab × 30 days × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡